GIP ANALOG AND HYBRID POLYPEPTIDES WITH SELECTABLE PROPERTIES

The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/...

Full description

Saved in:
Bibliographic Details
Main Authors LEWIS, DIANA Y, SOARES, CHRISTOPHER J, SRIVASTAVA, VED, YOUNG, ANDREW A, MACK, CHRISTINE M, DAESOUZA, LAWRENCE J, HANLEY, MICHAEL R, PITTNER, RICHARD A, GHOSH, SOUMITRA S, JODKA, CAROLYN M, ERICKSON, MARY, BARON, ALAIN D, JANSSEN, SAMUEL, LEVY, ODILE ESTHER, PARKES, DAVID G
Format Patent
LanguageEnglish
Published 30.03.2010
Online AccessGet full text

Cover

More Information
Summary:The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and/or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin- resistance, obesity, and diabetes mellitus of any kind, including type I, type 2, and gestational diabetes.
Bibliography:Application Number: SG20100009991